Claritas Pharmaceuticals Inc V.CLAS.H

Radikal Therapeutics Inc.

[indaknownewfie]

RADIKAL THERAPEUTICS 
Radikal Therapeutics, Inc. (RTX) was established in 2010 by Dr. Andrew Salzman to promote drug discovery and development by a core group of Inotek’s leading scientists (Jagtap, Southan, Murthy). With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, RTX has remained at the forefront of drug discovery for the past decade. RTX is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. Although varied in their structural targets and directed at diverse clinical needs, our technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents. The value of this concept was appreciated at a national level, when the US government awarded $84 million in BARDA funding to emergently develop the first potential antidote to chlorine inhalational lung injury, in response to the use of chlorine bombs in the war in Syria and the threat potential for chlorine gas to be used in mass terrorism and attacks on US military personnel.